LogicBio is a Lexington, MA-based genome editing company focused on delivering the benefits of genetic medicine to the fight against early onset childhood diseases. Logic’s approach is based on its core proprietary technology platform, GeneRide, which enables precise, durable and site-specific integration of a therapeutic transgene without exogenous nucleases or promoters by relying on the native process of homologous recombination. Logic is initially evaluating its technology in rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient’s life before irreversible disease pathology occurs. LogicBio’s lead product candidate, LB-001, has an active IND to support the initiation of the SUNRISE Phase 1/2 clinical trial in methylmalonic acidemia, or MMA, a life-threatening disease that presents at birth. LogicBio has also demonstrated preclinical proof of concept of its therapeutic platform in animal models for a number of other diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.